1. Home
  2. Products


ANEW MEDICAL is dedicated to realizing the potential of biologic, cell and gene therapies to offer transformative patient outcomes in areas of high unmet medical need by extending the reach of protein, cell, and gene therapies to highly prevalent neurodegenerative disorders like amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease as they are universally fatal neurodegenerative diseases. Our vision is to build a leading gene therapy company for the treatment of cancer and neurodegenerative diseases by progressing our α-Klotho gene therapy research programs and identifying, developing, and commercializing other novel gene therapy treatments for neurodegenerative diseases, cancer and other age-related pathologies.

We have assembled a portfolio of gene therapy candidates in partnership with leading scientific institutions and have built a team with extensive experience in the biotechnology commercialization and gene therapy space. Our team will pursue new innovations in vector design and delivery to optimize our investigational gene therapy product candidates for safety, potency, durability, and clinical response. We plan on building integrated internal development capabilities from product development through commercialization and focus on accelerating the pace of product development in the clinic. In addition, as part of our ongoing business strategy, we continue to explore potential opportunities to acquire or license new product candidates as well as opportunities for partnership or collaboration on our existing products in development.

There are currently four technologies managed by our team — (1) A cell therapy and gene therapy platform that uses a gene therapy approach to introduce a human gene that produces a therapeutic protein called “Klotho” inside the body to treat neurodegenerative diseases and other diseases of aging (a platform technology in-licensed from UAB); (2) a proprietary, patented technology platform with a library of melanocortin receptor-binding molecules (in-licensed from Teleost). The Company also acquired a (3) portfolio of “generic” drugs and (4) a license to “biosimilar” biologics technology (in-licensed from RLS) that will allow us to sell hard-to-source, difficult to find generic oncology drugs and off-patent biologic therapies. Our initial focus will be on our gene therapy research and development programs. With an initial focus on the therapeutic potential of the human α-Klotho gene, we find that there is limited competition investigating this target due to our intellectual property position and technology know-how.

Biologics and gene therapies are the future of medicine. Anew Medical, Inc. (“Anew Medical” or “ANEW” was formed in 2021 to develop cutting-edge biologic medicines for the treatment of chronic diseases – cancer, cardiovascular, and neurodegenerative disorders. As we age and get older, these diseases become the major cause of death or disablement. There are two wholly-owned subsidiaries under management by the Anew Medical team – Anew Biologics, Inc. uses state-of-the-art biologic therapies to treat cancer – using recombinant proteins made outside the body, and Anew Gene Therapy, Inc. which uses a gene therapy approach to introduce a gene to make therapeutic proteins inside the body – to either block factors causing disease or to replace human genes that have either shut down native protein production or have mutated to produce aberrant proteins that do not function at all.

Cell and Gene Therapy

This product holds longer-term potential for the treatment of Alzheimer’s disease and ALS (amyotrophic lateral sclerosis or “Lou Gehrig’s disease).

Melanocortin Receptor-Binding Molecules

Anew Medical licensed rights to certain technology and know-how in the field of gamma-melanocortins comprised of drug and peptide chemicals, API and pharmaceuticals that bind, affect, and potentially treat diseases directly or indirectly related to human MC1R receptors.

Essential Medicines

ANEW has secured licensed rights to the APIs (Active Pharmaceutical Ingredients) of a number of generic drugs that in short supply.


ANEW licensed rights to antibodies against VEGF and CD20 low risk product development.

This website may contain forward-looking statements that involve risks, uncertainties, and assumptions. All statements other than statements of historical fact could be deemed forward-looking statements, including any projections of revenues, gross margins, earnings, or other financial items; statements regarding strategies or plans for future operations; statements concerning our products; statements relating to the expected performance or benefits of our offerings; statements about current or future economic conditions; and any other statements of expectation or belief. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements, and therefore you should not rely on any forward-looking statements that we may make.

The risks and uncertainties referred to above include, but are not limited to, our history of losses and expectations as to future losses, limited operating history, competition, management of growth, development of the market for our therapeutics, market acceptance of our products, compliance with global laws and regulations, risks associated with maintaining a global business and global economic conditions, fluctuations in our operating results, and risks associated with regulatory approvals and compliance.

Anew Medical assumes no obligation for, and does not intend to update, any forward-looking statements.